For: | Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol 2018; 24(32): 3567-3582 [PMID: 30166855 DOI: 10.3748/wjg.v24.i32.3567] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v24/i32/3567.htm |
Number | Citing Articles |
1 |
Noémi Mónika Szeifert, Simon Szilágyi, Barbara Sebők, Márk Bérdi. A violens öngyilkossági kísérletek számának változása a COVID–19-járvány első két évében a Dr. Manninger Jenő Baleseti Központban.. Orvosi Hetilap 2023; 164(26): 1003 doi: 10.1556/650.2023.32819
|
2 |
Tushar Shukla, Bruce E. Sands. Novel Non-biologic Targets for Inflammatory Bowel Disease. Current Gastroenterology Reports 2019; 21(5) doi: 10.1007/s11894-019-0689-2
|
3 |
De-Gao He, Xi-Jie Chen, Juan-Ni Huang, Jun-Guo Chen, Min-Yi Lv, Tian-Ze Huang, Ping Lan, Xiao-Sheng He. Increased risk of colorectal neoplasia in inflammatory bowel disease patients with post-inflammatory polyps: A systematic review and meta-analysis. World Journal of Gastrointestinal Oncology 2022; 14(1): 348-361 doi: 10.4251/wjgo.v14.i1.348
|
4 |
Nicole L. Mancini, Luke Goudie, Warren Xu, Rasha Sabouny, Sruthi Rajeev, Arthur Wang, Nicolas Esquerre, Ala Al Rajabi, Timothy S. Jayme, Erik van Tilburg Bernandes, Yasmin Nasser, José G.P. Ferraz, Timothy Shutt, Jane Shearer, Derek M. McKay. Perturbed Mitochondrial Dynamics Is a Novel Feature of Colitis That Can Be Targeted to Lessen Disease. Cellular and Molecular Gastroenterology and Hepatology 2020; 10(2): 287 doi: 10.1016/j.jcmgh.2020.04.004
|
5 |
Cindy CY Law, Conor Bell, Deborah Koh, Yueyang Bao, Vipul Jairath, Neeraj Narula. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Cochrane Database of Systematic Reviews 2020; 2021(12) doi: 10.1002/14651858.CD013256.pub2
|
6 |
Wenjuan Liu, Zirong Dong, Kaiheng Liu, Yi Lu, Wei Wu, Jianping Qi, Zhongjian Chen. Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease. International Journal of Pharmaceutics 2021; 600: 120461 doi: 10.1016/j.ijpharm.2021.120461
|
7 |
Yago González-Lama, Elena Ricart, Daniel Carpio, Guillermo Bastida, Daniel Ceballos, Daniel Ginard, Ignacio Marin-Jimenez, Luis Menchen, Fernando Muñoz. Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus. BMJ Open Gastroenterology 2024; 11(1): e001246 doi: 10.1136/bmjgast-2023-001246
|
8 |
Sara Salvador-Martín, Beatriz López-Cauce, Olga Nuñez, Emilio J. Laserna-Mendieta, María I. García, Elena Lobato, Judith Abarca-Zabalía, María Sanjurjo-Saez, Alfredo J. Lucendo, Ignacio Marín-Jiménez, Luis A. Menchén, Luis A. López-Fernández. Genetic predictors of long-term response and trough levels of infliximab in crohn’s disease. Pharmacological Research 2019; 149: 104478 doi: 10.1016/j.phrs.2019.104478
|
9 |
Nikita Desai, Tarun Kaura, Maharaj Singh, Field F. Willingham, Surinder Rana, Saurabh Chawla. Epidemiology and Characteristics of Chronic Pancreatitis—Do the East and West Meet?. Gastro Hep Advances 2022; 1(6): 942 doi: 10.1016/j.gastha.2022.07.013
|
10 |
Balaji Venkataraman, Shreesh Ojha, Prasanna D. Belur, Bhoomendra Bhongade, Vishnu Raj, Peter D. Collin, Thomas E. Adrian, Sandeep B. Subramanya. Phytochemical drug candidates for the modulation of peroxisome proliferator‐activated receptor γ in inflammatory bowel diseases. Phytotherapy Research 2020; 34(7): 1530 doi: 10.1002/ptr.6625
|
11 |
Stuart Bloom, Tariq Iqbal, Chuka Nwokolo, Vipul Jairath, Jesse Hall, Bruce Dzyngel, Peter Gardzinski. 713 A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Influence of Immunosuppressants at Baseline. American Journal of Gastroenterology 2019; 114(1): S419 doi: 10.14309/01.ajg.0000592388.53875.b2
|
12 |
Cindy CY Law, Deborah Koh, Yueyang Bao, Vipul Jairath, Neeraj Narula. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Cochrane Database of Systematic Reviews 2019; doi: 10.1002/14651858.CD013256
|
13 |
Yan Xu, Aditi Sharma, Yang Chen, Honghui Zhou. What We Can Learn from Current Inflammatory Bowel Disease (IBD) Biological Therapy—Dose Regimen and Others. Current Pharmacology Reports 2019; 5(3): 115 doi: 10.1007/s40495-019-00180-x
|
14 |
Jing-Wei Mao. Small molecule agents in clinical management of inflammatory bowel disease: Current status and future prospects. World Chinese Journal of Digestology 2023; 31(22): 913 doi: 10.11569/wcjd.v31.i22.913
|
15 |
Yan Xu, Chuanpu Hu, Yang Chen, Xin Miao, Omoniyi J. Adedokun, Zhenhua Xu, Amarnath Sharma, Honghui Zhou. Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis. The Journal of Clinical Pharmacology 2020; 60(7): 889 doi: 10.1002/jcph.1582
|
16 |
Padhmanand Sudhakar, Dahham Alsoud, Judith Wellens, Sare Verstockt, Kaline Arnauts, Bram Verstockt, Severine Vermeire. Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All. Journal of Crohn's and Colitis 2022; 16(8): 1306 doi: 10.1093/ecco-jcc/jjac027
|
17 |
Michel Adamina, Stefanos Bonovas, Tim Raine, Antonino Spinelli, Janindra Warusavitarne, Alessandro Armuzzi, Oliver Bachmann, Palle Bager, Livia Biancone, Bernd Bokemeyer, Peter Bossuyt, Johan Burisch, Paul Collins, Glen Doherty, Alaa El-Hussuna, Pierre Ellul, Gionata Fiorino, Cornelia Frei-Lanter, Federica Furfaro, Christian Gingert, Paolo Gionchetti, Javier P Gisbert, Fernando Gomollon, Marien González Lorenzo, Hannah Gordon, Tibor Hlavaty, Pascal Juillerat, Konstantinos Katsanos, Uri Kopylov, Eduards Krustins, Torsten Kucharzik, Theodore Lytras, Christian Maaser, Fernando Magro, John Kenneth Marshall, Pär Myrelid, Gianluca Pellino, Isadora Rosa, Joao Sabino, Edoardo Savarino, Laurents Stassen, Joana Torres, Mathieu Uzzan, Stephan Vavricka, Bram Verstockt, Oded Zmora. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment. Journal of Crohn's and Colitis 2020; 14(2): 155 doi: 10.1093/ecco-jcc/jjz187
|
18 |
Sophie Restellini, Waqqas Afif. Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease. Journal of Clinical Medicine 2021; 10(6): 1242 doi: 10.3390/jcm10061242
|
19 |
Bob Geng, Timothy J. Craig. Small molecule drugs for atopic dermatitis, rheumatoid arthritis, and hereditary angioedema. Annals of Allergy, Asthma & Immunology 2022; 128(3): 263 doi: 10.1016/j.anai.2021.10.015
|
20 |
Irene Marafini, Silvia Sedda, Vincenzo Dinallo, Giovanni Monteleone. Inflammatory cytokines: from discoveries to therapies in IBD. Expert Opinion on Biological Therapy 2019; 19(11): 1207 doi: 10.1080/14712598.2019.1652267
|
21 |
Peter Kienle. Impact of Modern Drug Therapy on Surgery: Crohn's Disease. Visceral Medicine 2018; 34(6): 422 doi: 10.1159/000495127
|
22 |
Boris Gole, Uroš Potočnik. Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis. Cells 2019; 8(6): 515 doi: 10.3390/cells8060515
|
23 |
Ciro Romano, Sergio Esposito, Roberta Ferrara, Giovanna Cuomo. Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions. Expert Opinion on Biological Therapy 2020; 20(1): 49 doi: 10.1080/14712598.2020.1689953
|
24 |
Elena Milanesi, Maria Dobre, Teodora E. Manuc, Gabriel Becheanu, Cristian G. Tieranu, Elena M. Ionescu, Mircea Manuc. Mucosal gene expression changes induced by anti‐TNF treatment in inflammatory bowel disease patients. Drug Development Research 2019; 80(6): 831 doi: 10.1002/ddr.21566
|
25 |
Maria Chiara Ditto, Simone Parisi, Gianpiero Landolfi, Richard Borrelli, Cristina Realmuto, Annacarla Finucci, Gian Paolo Caviglia, Davide Giuseppe Ribaldone, Marco Astegiano, Anna Zanetti, Greta Carrara, Carlo Alberto Scirè, Marco Antivalle, Piercarlo Sarzi-Puttini, Enrico Fusaro. Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis. RMD Open 2021; 7(3): e001755 doi: 10.1136/rmdopen-2021-001755
|
26 |
Jörg D. Schulzke, Michael Fromm. Ion Transport Across Epithelial Tissues and Disease. Physiology in Health and Disease 2020; : 77 doi: 10.1007/978-3-030-55310-4_3
|
27 |
Michel Adamina, Gionata Fiorino. At the Crossroads of Caution and Intervention: Anti-TNF Therapy Prior to Elective CD Surgery. Journal of Crohn's and Colitis 2021; 15(10): 1778 doi: 10.1093/ecco-jcc/jjab092
|
28 |
Cecilia Dell’Avalle, Ferdinando D’Amico, Roberto Gabbiadini, Arianna Dal Buono, Nicola Pugliese, Alessandra Zilli, Federica Furfaro, Gionata Fiorino, Mariangela Allocca, Laurent Peyrin-Biroulet, Silvio Danese. JAK inhibitors in crohn’s disease: ready to go?. Expert Opinion on Investigational Drugs 2022; 31(2): 145 doi: 10.1080/13543784.2022.2032639
|
29 |
Javier Plaza, Alejandro Mínguez, Guillermo Bastida, Remedios Marqués, Pilar Nos, Jose Luis Poveda, Inés Moret-Tatay. Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review. International Journal of Molecular Sciences 2024; 25(7): 3717 doi: 10.3390/ijms25073717
|
30 |
Cynthia Morvillo, Katherine Vinci, Lauren Hedenschoug, Leah Mancini, Carrie Mize, Kayce Tugg, Steven Stein. Risks and Safety of Advanced Therapies and Biologics in Inflammatory Bowel Disease. Gastroenterology Nursing 2020; 43(4): E159 doi: 10.1097/SGA.0000000000000523
|
31 |
Edvin Brusač, Mario-Livio Jeličić, Daniela Amidžić Klarić, Biljana Nigović, Nikša Turk, Ilija Klarić, Ana Mornar. Pharmacokinetic Profiling and Simultaneous Determination of Thiopurine Immunosuppressants and Folic Acid by Chromatographic Methods. Molecules 2019; 24(19): 3469 doi: 10.3390/molecules24193469
|
32 |
Michel Adamina, Silvia Minozzi, Janindra Warusavitarne, Christianne Johanna Buskens, Maria Chaparro, Bram Verstockt, Uri Kopylov, Henit Yanai, Stephan R Vavricka, Rotem Sigall-Boneh, Giuseppe S Sica, Catherine Reenaers, Georgios Peros, Konstantinos Papamichael, Nurulamin Noor, Gordon William Moran, Christian Maaser, Gaetano Luglio, Paulo Gustavo Kotze, Taku Kobayashi, Konstantinos Karmiris, Christina Kapizioni, Nusrat Iqbal, Marietta Iacucci, Stefan Holubar, Jurij Hanzel, João Guedelha Sabino, Javier P Gisbert, Gionata Fiorino, Catarina Fidalgo, Pierre Ellu, Alaa El-Hussuna, Joline de Groof, Wladyslawa Czuber-Dochan, María José Casanova, Johan Burisch, Steven Ross Brown, Gabriele Bislenghi, Dominik Bettenworth, Robert Battat, Raja Atreya, Mariangela Allocca, Manasi Agrawal, Tim Raine, Hannah Gordon, Pär Myrelid. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment. Journal of Crohn's and Colitis 2024; 18(10): 1556 doi: 10.1093/ecco-jcc/jjae089
|
33 |
Sumaiah J. Alarfaj, Sally Abdallah Mostafa, Walaa A. Negm, Thanaa A. El-Masry, Marwa Kamal, Mohamed Elsaeed, Ahmed Mohamed El Nakib. Mucosal Genes Expression in Inflammatory Bowel Disease Patients: New Insights. Pharmaceuticals 2023; 16(2): 324 doi: 10.3390/ph16020324
|
34 |
Simon P. Borg-Bartolo, Ray Kiran Boyapati, Jack Satsangi, Rahul Kalla. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Research 2020; 9: 54 doi: 10.12688/f1000research.20928.1
|
35 |
Young-Jae Hwang, Seung-Joo Nam, Wanjoo Chun, Song In Kim, Sung Chul Park, Chang Don Kang, Sung Joon Lee, Partha Mukhopadhyay. Anti-inflammatory effects of apocynin on dextran sulfate sodium-induced mouse colitis model. PLOS ONE 2019; 14(5): e0217642 doi: 10.1371/journal.pone.0217642
|